

# Sex- and Gender-specific Observations and Implications for COVID-19

Lauren A. Walter, MD\*†  
Alyson J. McGregor, MD, MA\*†

\*University of Alabama at Birmingham, Department of Emergency Medicine, Birmingham, Alabama

†Warren Alpert Medical School of Brown University, Department of Emergency Medicine, Providence, Rhode Island

Section Editor: Mark I. Langdorf, MD, MHPE

Submission history: Submitted April 2, 2020; Accepted April 3, 2020

Electronically published April 10, 2020

Full text available through open access at [http://escholarship.org/uc/uciem\\_westjem](http://escholarship.org/uc/uciem_westjem)

DOI: 10.5811/westjem.2020.4.47536

[West J Emerg Med. 2020;21(3)507-509.]

*Disclaimer: Due to the rapidly evolving nature of this outbreak, and in the interests of rapid dissemination of reliable, actionable information, this paper went through expedited peer review. Additionally, information should be considered current only at the time of publication and may evolve as the science develops. On February 11, 2020, the World Health Organization renamed the virus COVID-19.*

This is a critical time for medicine. As we observe the exponential rise in the number of individuals in the United States (US) who are infected with COVID-19, we try to prepare. Those in the front lines are trying to protect themselves and their patients with the daily ration of personal protective equipment and ventilation assistive equipment. Many individuals are racing against time to develop the needed novel treatments and vaccines. Public health officials work with what little information is known in order to make effective recommendations for prevention. However, at this pivotal time in history where every detail obtained by US health officials could be lifesaving, we are leaving out vital information.

Descriptive and observational data from Wuhan, China, note that the majority (51%-66.7%) of affected patients have been male. In addition, male sex was an independent risk factor associated with refractory disease and death (2.8% death rate for men vs 1.7% for female).<sup>1,2</sup> Currently, men represent 58% of COVID-19 infected patients in Italy and 70% of COVID-related deaths.<sup>3</sup> As coronavirus cases and deaths in the US continue to soar, sex-specific, comprehensive data with regard to US patients is not yet available.

Sex- and gender-based medicine (SGBM) incorporates how biological *sex* and the sociocultural aspects of *gender* affect health and illness. It acknowledges the interrelationship between sex and gender on health outcomes and promotes consideration of this variable in both research and clinical practice. SGBM has demonstrated significant evidence-based impact on cardiovascular disease, stroke,

sports medicine, and pain management, just to name a few

Sex and gender differences have been observed in infectious diseases previously. On a broad and critical scale, Nasir et al demonstrated that males with all-cause infectious sepsis have a 70% greater mortality than their female counterparts. Likewise, respiratory infection-specific epidemiological data from recent SARS (2003) and MERS (2012) outbreaks demonstrated a significantly higher case fatality rate in males as compared to females, 21.9% vs 13.2%.<sup>4,5</sup>

## Sex-specific Factors

Is the biological male more susceptible to an increased severity of infection? Or does the biological woman have natural protection against these viruses? In a 2017 *BMJ* article, Dr. Kyle Sue demonstrated the effect of sex hormones, estrogen and testosterone, on immune system response and engagement, resulting in a less robust immunologic response in males and subsequent increased morbidity and mortality from viral respiratory illnesses.<sup>6</sup> In addition, the X chromosome carries the largest number of immune-related genes in the human genome, perhaps also contributing to female's superior immune response (as well as a female preponderance in autoimmune diseases).<sup>7</sup>

Angiotensin-converting enzyme 2 (ACE2) and its role in viral transmission and associated morbidity has also been a topic of recent COVID-19 associated discussion. ACE2 receptors on pulmonary endothelium serve as a main entry point for coronavirus. Several previous animal models have demonstrated increased ACE2 activity in the male or ovariectomized model, suggesting a sex hormone influence.<sup>8</sup> The gene for the ACE2 receptor is also, interestingly, on the X chromosome.<sup>9</sup>

## Gender-specific Factors

Behavioral and cultural variables have also influenced current COVID-19 epidemiology. Smoking in particular has

been implicated as a significant contributor to disease severity, and gender-specific patterns are quite apparent here. The smoking rate in China is much higher in men than in women (288 million men vs 12.6 million women; 2018 data).<sup>10</sup> Likewise, in Italy, men are more likely to smoke than women at any age (1.12x to 1.7x, depending on age cohort; 2018 data).<sup>11</sup> Similar gender-specific trends are also present in the US, where 17.6% of smokers are men as compared to 13.6% of women.<sup>12</sup>

In addition, as the traditional caregivers and coordinators of care for their loved ones, women, particularly working mothers, tend to spend more time than men focused on medical issues related to both their own healthcare and that of their families.<sup>13</sup> In general, men are more likely to engage in health-related risks which, even prior to the COVID-19 pandemic, has been shown to result in higher rates of injury and disease.<sup>14</sup> Suen et al demonstrated in 2019 that being a middle-aged female was a protective factor with regard to hand hygiene knowledge and practice.<sup>15</sup>

### Implications for COVID-19 Management

As clinical researchers and pharmaceutical companies race to find an effective treatment strategy or vaccine for COVID-19, no sex- or gender-specific recommendations have been released with regard to the care and management of individuals affected by the novel coronavirus. Appreciating the weight of known sex- and gender-specific epidemiologic observations thus far, however, will be an important highlight of the information gathered to date. This, combined with what is already known about sex- and gender-based pulmonary and infectious disease pathology, may lead to important treatment breakthroughs that consider the sex and/or gender of patient in the comprehensive management plan.

In addition, the current pandemic weighs heavily on emotional wellness along with physical health. COVID-19 has also released a contagion of fear, anxiety, and stigma that will have implications for downstream mental health effects including post-traumatic stress disorder (PTSD). In general, the prevalence of PTSD has been shown to be substantially higher in women.<sup>16</sup> This has been re-substantiated in the setting of the COVID-19 outbreak in Wuhan, China, where women scored significantly higher on the PCL-5 (DSM-5 self-report measure for PTSD) than men, including higher rates of re-experiencing and negative alterations in cognition or mood.<sup>17</sup> Early recognition and effective treatment can ameliorate the burden of PTSD on both the individual and society, particularly for women who have been shown to have a modest advantage with regard to treatment response.<sup>18</sup>

### Future Considerations

Since 2016, the NIH has required inclusion of sex as a biological variable (SABV) in the study design for funded

#### *Population Health Research Capsule*

What do we already know about this issue?

*COVID-19 represents an unparalleled public health crisis. Like many other infectious diseases, sex and gender differences in health outcomes have already been globally observed.*

What was the research question?

*We sought to summarize and explain known COVID-19-related sex and gender differences.*

What was the major finding of the study?

*Sex and gender differences are having significant impacts on current COVID-19 health outcomes.*

How does this improve population health?

*This perspective brings attention to the importance of sex and gender; specifically as they impact current clinical management and research during the COVID-19 pandemic.*

research.<sup>19</sup> Recognizing the weight these variables play in disease outcome should result in universal adoption of SABV as scientists develop and engage in COVID-19 research. While men appear to be disproportionately affected and at risk for COVID-19 infection and associated morbidity, researchers should avoid the slippery slope of the traditional male-dominant test and analysis approach.

When considering pharmaceutical therapy advances, several previous studies have established that women are much more likely to experience adverse drug reactions (ADR) than men.<sup>20</sup> In fact, historically the majority of drugs recalled from the market were done so due to serious ADRs reported by women, quite often because they were never tested on women during clinical trials. Several sex-specific pharmacokinetic and pharmacodynamic differences have been well documented.<sup>21</sup>

Yes, time is of the essence right now; however, COVID-19 does not get a “pass” in considering sex and gender when gathering data or testing treatments. Sex and gender have already proven to be crucial variables in the short history of COVID-19; they will continue to be factors of marked importance. Making healthcare providers and researchers aware of their impact in real time will be crucial to the integration of susceptibility profiles and improving outcomes during an active public health crisis.

**Address for Correspondence:** Lauren A. Walter, MD, University of Alabama at Birmingham, Department of Emergency Medicine, OHB 251, 619 19th St S, Birmingham, AL 35249. Email: lwalter@uabmc.edu.

**Conflicts of Interest:** By the WestJEM article submission agreement, all authors are required to disclose all affiliations, funding sources and financial or management relationships that could be perceived as potential sources of bias. No author has professional or financial relationships with any companies that are relevant to this study. There are no conflicts of interest or sources of funding to declare.

**Copyright:** © 2020 Walter et al. This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) License. See: <http://creativecommons.org/licenses/by/4.0/>

## REFERENCES

1. Mo P, Xing Y, Xiao Y, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. *Clin Infect Dis*. 2020. In Press.
2. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395(10223):507–13.
3. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? *Lancet*. 2020;S0140-6736(20)30627-9.
4. Channappanavar R, Fett C, Mack M, et al. Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection. *J Immunol*. 2017;198(10):4046–53.
5. Matsuyama R, Nishiura H, Kutsuna S, et al. Clinical determinants of the severity of Middle East respiratory syndrome (MERS): a systematic review and meta-analysis. *BMC Public Health*. 2016;16(1):1203.
6. Sue K. The science behind “man flu.” *BMJ*. 2017;359:j5560.
7. Schurz H, Salie M, Tromp G, et al. The X chromosome and sex-specific effects in infectious disease susceptibility. *Hum Genomics*. 2019;13(1):2.
8. Liu J, Ji H, Zheng W, et al. Sex differences in renal angiotensin converting enzyme 2 (ACE2) activity are 17 $\beta$ -oestradiol-dependent and sex chromosome-independent. *Biol Sex Differ*. 2010;1(1):6.
9. Patel SK, Velkoska E, Freeman M, et al. From gene to protein—experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension. *Front Physiol*. 2014;5:227.
10. Cai H. Sex difference and smoking predisposition in patients with COVID-19. *Lancet Respir Med*. 2020. In Press.
11. Statista Research Department. “Number of Smokers by Age and Gender in Italy 2018.” *Statista*. Available at: [www.statista.com/statistics/501615/italy-smokers-by-age-and-gender/](http://www.statista.com/statistics/501615/italy-smokers-by-age-and-gender/). Accessed March 27, 2020.
12. National Institute on Drug Abuse. “Are There Gender Differences in Tobacco Smoking?” *NIDA*. Available at: [www.drugabuse.gov/publications/research-reports/tobacco-nicotine-e-cigarettes/are-there-gender-differences-in-tobacco-smoking](http://www.drugabuse.gov/publications/research-reports/tobacco-nicotine-e-cigarettes/are-there-gender-differences-in-tobacco-smoking). Accessed March 27, 2020.
13. “A Health Care Consumer Gender Gap.” *Managed Care Magazine*. Available at: [www.managedcaremag.com/archives/2016/8/health-care-consumer-gender-gap](http://www.managedcaremag.com/archives/2016/8/health-care-consumer-gender-gap). Accessed March 27, 2019.
14. Harris CR, Jenkins M. Gender differences in risk assessment: Why do women take fewer risks than men? *Judgm Decis Mak*. 2006;1(1):48-63.
15. Suen LKP, So ZYY, Yeung SKW, et al. Epidemiological investigation on hand hygiene knowledge and behaviour: a cross-sectional study on gender disparity. *BMC Public Health*. 2019;19(1):401.
16. K Farhood L, Fares S, Hamady C. PTSD and gender: Could gender differences in war trauma types, symptom clusters and risk factors predict gender differences in PTSD prevalence? *Arch Womens Ment Health*. 2018;21(6):725–33.
17. Liu N, Zhang F, Wei C. Prevalence and predictors of PTSS during COVID-19 Outbreak in China Hardest-hit Areas: Gender differences matter. *Psychiatry Res*. 2020. In Press.
18. Blain LM, Galovksi TE, Robinson T. Gender differences in recovery from posttraumatic stress disorder: a critical review. *Aggress Violent Behav*. 2010;15(6):463-74.
19. “NIH Policy on Sex as a Biological Variable.” *National Institutes of Health*, U.S. Department of Health and Human Services. Available at: [orwh.od.nih.gov/sex-gender/nih-policy-sex-biological-variable](http://orwh.od.nih.gov/sex-gender/nih-policy-sex-biological-variable). Accessed March 27<sup>th</sup>, 2020.
20. Tran C, Knowles SR, Liu BA, et al. Gender differences in adverse drug reactions. *J Clin Pharmacol*. 1998;38(11):1003–9.
21. Franconi F, Campesi I. Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women. *Br J Pharmacol*. 2014;171(3):580–94.